Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918715 | 0.85 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPMAPT | |
| SCHEMBL539900 | 0.85 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPMAPT | |
| SCHEMBL30918718 | 0.85 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPMAPT | |
| SCHEMBL20929429 | 0.85 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPMAPT | |
| SCHEMBL3733352 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPMAPT | |
| SCHEMBL3733204 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPMAPT | |
| SCHEMBL20929165 | 0.78 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPMAPT | |
| SCHEMBL5938340 | 0.75 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPCYP3A4 | |
| SCHEMBL2198273 | 0.75 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPMAPT | |
| SCHEMBL8107978 | 0.75 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242285-B2 | N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-2008999-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | TERT, CBR1, TELO2 | CHRM2 1573/4885CHRM1 622/4885CHRM3 1930/4885 |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | TERT, CBR1, TELO2 | CHRM2 1573/4885CHRM1 622/4885CHRM3 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.